Citation: D. Kahn et al., A phase II study of [Y-90] yttrium-capromab pendetide in the treatment of men with prostate cancer recurrence following radical prostatectomy, CANC BIO R, 14(2), 1999, pp. 99-111
Authors:
Manyak, MJ
Hinkle, GH
Olsen, JO
Chiaccherini, RP
Partin, AW
Piantadosi, S
Burgers, JK
Texter, JH
Neal, CE
Libertino, JA
Wright, GL
Maguire, RT
Citation: Mj. Manyak et al., Immunoscintigraphy with indium-111-capromab pendetide: Evaluation before definitive therapy in patients with prostate cancer, UROLOGY, 54(6), 1999, pp. 1058-1063
Authors:
Polascik, TJ
Manyak, MJ
Haseman, MK
Gurganus, RT
Rogers, B
Maguire, RT
Partin, AW
Citation: Tj. Polascik et al., Comparison of clinical staging algorithms and (111)indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients, CANCER, 85(7), 1999, pp. 1586-1592